Introduction: H Pylori is a gram-negative bacterium, spiral-shaped, motile , and microaerophilic with polar flagella.. H Pylori can lead to gastric peptic ulcer diseases, and gastric cancer[1].
H pylori infection, one of the most common bacterial infections, affects approximately 50% of the world's population[2].
H Pylori Treatment remains a challenge[3-6].
Vaccination is the best option for H Pylori but now we dont have it. Thus antibiotic therapy is preferable than other options[7-12].
Methods: We will include studies assessing the treatment of H pylori published in the last 9 years. We will search the databased of Pubmed, Scopus, Cochrane central register of controlled trials. In all, 164 studies were obtained from the original search algorithm, of which 142 were excluded because they were duplicated, not RCTs, or irrelevant to the current analysis. 22 studies were evaluated.
Results: In overall both BQT and HDDT can achieve similar eradication rates for Helicobacter pylori infection, and generally HDDT has fewer side effects. The most sensitive drug is rifabutin and the lowest sensitive drug is Metronidazole in the world. In H pylori antibiotic resistance to clarithromycin and Levofloxacin has increased during the last 9 years.
These findings stress the need for appropriate surveillance programs, improved antimicrobial regulation, and increased public awareness.
Conclusion: These results indicate that antibiotic resistance to clarithromycin and levofloxacin has increased. The least sensitive drug is metronidazole. The results indicate the need for a new program to eradicate H pylori infection.